Vol. 5 No. 10 (2025)
Reimbursement Recommendations

Pembrolizumab (Keytruda)

decorative image of the issue cover

Published October 20, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Keytruda in combination with chemoradiotherapy be reimbursed by public drug plans for the treatment of Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) 2014 stage III to IVA cervical cancer if certain conditions are met.
  • Keytruda in combination with chemoradiotherapy should only be covered to treat patients who have locally advanced cervical cancer (LACC) (stage III to IVA FIGO 2014 classification) that has not been previously treated, with histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix, and who have a relatively good health (as measured by performance status) at the start of treatment.
  • Keytruda in combination with chemoradiotherapy should only be reimbursed if prescribed by clinicians with experience with immuno-oncology and chemoradiotherapy and in treating cervical cancer, and the cost of Keytruda is reduced.